Treatment of androgen excess in adolescent girls: Ethinylestradiol- cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 11, 2011, Pages 3361-3366

  Ibáñez, Lourdes ^a,b   Diaz, Marta ^a,b   Sebastiani, Giorgia ^a,b   Sánchez Infantes, David ^a,b   Salvador, Cristina ^a   Lopez Bermejo, Abel ^c   De Zegher, Francis ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; DIANE; DIANE 35 DIARIO; FLUTAMIDA; FLUTAMIDE; FOLLISTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOLECULAR WEIGHT ADIPONECTIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMINA; PIOGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ACNE; ADOLESCENT; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID LIVER LEVEL; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; UNIVERSITY HOSPITAL;

ABDOMINAL FAT; ADOLESCENT; ANDROGEN ANTAGONISTS; BODY COMPOSITION; CYPROTERONE ACETATE; DRUG COMBINATIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; METFORMIN; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 80655137222     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1671     Document Type: Article

References (33)

1. Ehrmann DA 2005 Polycystic ovary syndrome. N Engl J Med 352: 1223-1236
2. Rosenfield RL 2005 Hirsutism. N Engl J Med 353:2578-2588 (Pubitemid 41785895)
3. Martin KA, Chang RJ, Ehrmann DA, Ibáñez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM, Swiglo BA 2008 Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93:1105-1120 (Pubitemid 351519694)
4. Norman RJ, Dewailly D, Legro RS, Hickey TE 2007 Polycystic ovary syndrome. Lancet 370:685-697 (Pubitemid 47285318)
5. Franks S, Layton A, Glasier A 2008 Cyproterone acetate/ethinyl oestradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod 23:231-232 (Pubitemid 351651255)
6. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez- Bermejo E, Lasunción MA, Escobar-Morreale HF 2007 Comparison of ethinyl-oestradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92:2453-2461
7. de Zegher F, Lopez-Bermejo A, Ibáñez L 2009 Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab 20:418-423
8. Burghen GA, Givens JR, Kitabchi AE 1980 Correlation of hyperandrogenism with hyperinsulinaemia in polycystic ovarian disease. J Clin Endocrinol Metab 50:113-116 (Pubitemid 10203585)
9. Chang RJ, Nakamura RM, Judd HL, Kaplan SA 1983 Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-359 (Pubitemid 13032489)
10. Barbieri RL, Smith S, Ryan KJ 1988 The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 50:197-212
11. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800 (Pubitemid 28009567)
12. Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, Hellström M, Lönn L, Olivecrona G, Stener-Victorin E, Lönn M 2011 Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 96:E304-E311
13. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F 2011 Early metformin therapy (age 8-12 yr) in girls with precocious pubarche to reduce hirsutism, androgen excess and oligomenorrhea in adolescence. J Clin Endocrinol Metab 96:E1262-E1267
14. Ibáñez L, López-Bermejo A, del Rio L, Enríquez G, Valls C, de Zegher F 2007 Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab 92:1710-1714 (Pubitemid 46997176)
15. Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, Valls C, de Zegher F 2008 Pioglitazone (7.5 mg/d) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high-molecular-weight adiponectin. Clin Endocrinol (Oxf) 68:317-320
16. Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, del Río L, de Zegher F 2009 Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol (Oxf) 71:351-357
17. Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, Del Río L, de Zegher F 2010 Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecol Endocrinol 26:869-873
18. Ibáñez L, Potau N, Zampolli M, Prat N, Virdis R, Vicens-Calvet E, Carrascosa A 1996 Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab 81:1237-1243 (Pubitemid 26083998)
19. Ibáñez L, de Zegher F 2004 Ethinylestradiol-drospirenone, flutamide- metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89:1592-1597 (Pubitemid 38507907)
20. Flanagan JN, Linder K, Mejhert N, Dungner E, Wahlen K, Decaunes P, Rydén M, Björklund P, Arver S, Bhasin S, Bouloumie A, Arner P, Dahlman I 2009 Role of follistatin in promoting adipogenesis in women. J Clin Endocrinol Metab 94:3003-3009
21. Ibáñez L, de Zegher F 2006 Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 12:243-252
22. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F 2000 Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidaemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85: 3526-3530
23. Ibáñez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F 2001 Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 86:3595-3598 (Pubitemid 32755948)
24. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger DB, de Zegher F 2002 Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 87:2870-2874 (Pubitemid 34655356)
25. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F 2003 Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 88:2600-2606 (Pubitemid 36724431)
26. Ibáñez L, Valls C, Cabré S, de Zegher F 2004 Flutamide-metformin plus ethinyloestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab 89: 4716-4720 (Pubitemid 39244493)
27. Ibáñez L, de Zegher F 2005 Flutamide-metformin plus ethinylestradiol- drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at start and after more than one year of therapy. J Clin Endocrinol Metab 90:39-43 (Pubitemid 40116631)
28. de Zegher F, Ibáñez L 2010 Low-dose flutamide for hirsutism: into the limelight, at last. Nat Rev Endocrinol 6:421-422
29. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Blüher M, Griffin PR, Spiegelman BM 2010 Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature 466:451-456
30. Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ 2011 Arole for central nervous system PPAR-γ in the regulation of energy balance. Nat Med 17:623-626
31. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS 2005 Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-18080 (Pubitemid 41389052)
32. O'Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM 2010 High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab 95:1378-1385
33. Tao T, Wickham 3rd EP, Fan W, Yang J, Liu W 2010 Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance. Eur J Endocrinol 163:399-406